Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

185.62 +3.31 (+1.82%)
Official Closing Price Updated: 4:10 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
74 75 Next >
Earnings Scheduled For January 31, 2025
Via Benzinga
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement. 
Via Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
Via Benzinga
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
Via The Motley Fool
Why AbbVie Stock Popped While the Market Flopped on Monday
Via The Motley Fool
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors. 
Via Benzinga
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better. 
Via The Motley Fool
Topics Intellectual Property
AbbVie Unusual Options Activity For January 10
Via Benzinga
Assessing AbbVie: Insights From 17 Financial Analysts
Via Benzinga
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
Via The Motley Fool
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Top Research Reports For Visa, AbbVie & Analog Devices
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc., Analog Devices, Inc. (ADI), and a micro-cap stock Precipio, Inc. 
Via Talk Markets
Topics Stocks / Equities
10 One Decision Stocks To Buy Now
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio
Via The Motley Fool
3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees
Via The Motley Fool
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
3 Incredible Dividend Stocks to Buy in 2025
These wildly successful companies are poised to keep your dividend portfolio healthy in 2025 and beyond. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.